![A woman stands behind a chair](/sites/default/files/styles/article_headlines/public/2024-02/20240127_024056305_ios.jpeg?itok=zU6HLkoD)
Please do not leave this page until complete. This can take a few moments.
AffyImmune Therapeutics, a biopharmaceutical company headquartered in Natick, has promoted Chief Operating Officer Matt Britz to the role of CEO and named Pete Gelinas as its new senior vice president of chemistry, manufacturing, and controls.
Britz, who joined AffyImmune as its senior vice president, business development in June 2021, has 28 years of life science-related experience, according to a press release issued by the company on Tuesday. Britz is the first CEO in the company’s history.
AffyImmune is working to develop CAR T cell therapies, which utilizes patients’ own immune systems to target and destroy cancer cells. The company has 11 local employees and 24 employees company-wide, according to data submitted by the company to the WBJ Research Department.
“Matt has been an instrumental part of AffyImmune’s growth in the past two years,” said Simone Song, chairperson of the board of directors for AffyImmune, and founder and senior partner at ORI Capital, which has invested in AffyImmune and announced a $260-million raise in February. “Matt has executed a focused business strategy supported by insights generated from our big data platform ORIzon, which has led to promising early clinical results for AffyImmune’s lead program AIC100 in advanced thyroid cancer.”
Britz previously served as senior vice president and head of business development at Minerva Biotechnologies, a Waltham-based biotechnology company. He holds a MBA and a master’s degree in biology from Washington University in St. Louis and a bachelor’s degree in chemical engineering and biology from the Massachusetts Institute of Technology in Cambridge.
“I’m honored to lead AffyImmune’s efforts in advancing affinity-tuned CAR T therapies, building upon the solid foundation we’ve established in the last few years,” Britz said in the press release. “Together, we're well-positioned to make significant advancements in addressing the challenges of solid cancers to improve patient outcomes."
Prior to being hired in the newly created role of AffyImmune’s senior vice president of chemistry, manufacturing, and controls, Gelnias served as head of manufacturing and technical operations at ElevateBio, a biotechnology research and development firm in Waltham. He graduated from Springfield College with a bachelor’s degree in sports biology, according to his LinkedIn profile.
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments